IMARC Group has recently released a report titled “Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033” that presents a comprehensive assessment of the heart failure market size, latest trends, and growth forecast. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the global market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.
Heart failure refers to a chronic, progressive ailment in which the heart is not able to pump enough blood to meet the needs of the body. It can happen due to a wide range of factors, such as high blood pressure, a previous heart attack, damage to the heart muscle, etc. The most common symptoms of this condition include a rapid or irregular heartbeat, swelling in the legs and feet, and shortness of breath. Numerous tests, such as the electrocardiogram (ECG), echocardiography, chest x-ray, and blood tests, are performed to identify and prevent heart failure. The treatment usually includes a combination of lifestyle changes as well as medication to improve the heart’s ability to pump blood. Severe cases may also require surgeries and heart transplants.
Request a Free Sample Report: https://www.imarcgroup.com/heart-failure-market/requestsample
Market Trend:
The expanding geriatric population, which is more susceptible to the risk of developing heart diseases, is primarily driving the heart failure market. Additionally, the increasing number of individuals with heart problems owing to obesity and a lack of physical activity is also augmenting the market growth. Moreover, the escalating incidences of numerous associated risk factors, such as excessive drinking of alcoholic beverages, unhealthy dietary habits, etc., are propelling the occurrence of heart diseases. This, in turn, is creating vast growth opportunities for the market. Additionally, the growing adoption of angiotensin-converting-enzyme (ACE) inhibitors, which relax the blood vessels and allow the heart to pump blood easily, is positively impacting the market growth. Besides this, the emerging popularity of diuretics to remove excess fluid from the body, which can help minimize heart failure symptoms, and the rising investments by the leading market players to introduce advanced medications are anticipated to propel the heart failure market in the coming years.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the heart failure market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the heart failure market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/heart-failure-market
Key Questions Answered in this Report:
- How has the heart failure market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the heart failure market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the heart failure market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Heart Failure – Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Heart Failure – Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Heart Failure – Epidemiology and Patient Population
7.1 Epidemiology – Key Insights
7.2 Epidemiology Scenario – Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2022)
7.2.2 Epidemiology Forecast (2023-2033)
7.2.3 Epidemiology by Age (2017-2033)
7.2.4 Epidemiology by Gender (2017-2033)
7.2.5 Epidemiology by Type (2017-2033)
7.2.6 Diagnosed Cases (2017-2033)
7.2.7 Patient Pool/Treated Cases (2017-2033)
7.3 Epidemiology Scenario – United States
7.3.1 Epidemiology Scenario (2017-2022)
7.3.2 Epidemiology Forecast (2023-2033)
7.3.3 Epidemiology by Age (2017-2033)
7.3.4 Epidemiology by Gender (2017-2033)
7.3.5 Epidemiology by Type (2017-2033)
7.3.6 Diagnosed Cases (2017-2033)
7.3.7 Patient Pool/Treated Cases (2017-2033)
7.4 Epidemiology Scenario – Germany
7.4.1 Epidemiology Scenario (2017-2022)
7.4.2 Epidemiology Forecast (2023-2033)
7.4.3 Epidemiology by Age (2017-2033)
7.4.4 Epidemiology by Gender (2017-2033)
7.4.5 Epidemiology by Type (2017-2033)
7.4.6 Diagnosed Cases (2017-2033)
7.4.7 Patient Pool/Treated Cases (2017-2033)
7.5 Epidemiology Scenario – France
7.5.1 Epidemiology Scenario (2017-2022)
7.5.2 Epidemiology Forecast (2023-2033)
7.5.3 Epidemiology by Age (2017-2033)
7.5.4 Epidemiology by Gender (2017-2033)
7.5.5 Epidemiology by Type (2017-2033)
7.5.6 Diagnosed Cases (2017-2033)
7.5.7 Patient Pool/Treated Cases (2017-2033)
7.6 Epidemiology Scenario – United Kingdom
7.6.1 Epidemiology Scenario (2017-2022)
7.6.2 Epidemiology Forecast (2023-2033)
7.6.3 Epidemiology by Age (2017-2033)
7.6.4 Epidemiology by Gender (2017-2033)
7.6.5 Epidemiology by Type (2017-2033)
7.6.6 Diagnosed Cases (2017-2033)
7.6.7 Patient Pool/Treated Cases (2017-2033)
7.7 Epidemiology Scenario – Italy
7.7.1 Epidemiology Scenario (2017-2022)
7.7.2 Epidemiology Forecast (2023-2033)
7.7.3 Epidemiology by Age (2017-2033)
7.7.4 Epidemiology by Gender (2017-2033)
7.7.5 Epidemiology by Type (2017-2033)
7.7.6 Diagnosed Cases (2017-2033)
7.7.7 Patient Pool/Treated Cases (2017-2033)
7.8 Epidemiology Scenario – Spain
7.8.1 Epidemiology Scenario (2017-2022)
7.8.2 Epidemiology Forecast (2023-2033)
7.8.3 Epidemiology by Age (2017-2033)
7.8.4 Epidemiology by Gender (2017-2033)
7.8.5 Epidemiology by Type (2017-2033)
7.8.6 Diagnosed Cases (2017-2033)
7.8.7 Patient Pool/Treated Cases (2017-2033)
7.9 Epidemiology Scenario – Japan
7.9.1 Epidemiology Scenario (2017-2022)
7.9.2 Epidemiology Forecast (2023-2033)
7.9.3 Epidemiology by Age (2017-2033)
7.9.4 Epidemiology by Gender (2017-2033)
7.9.5 Epidemiology by Type (2017-2033)
7.9.6 Diagnosed Cases (2017-2033)
7.9.7 Patient Pool/Treated Cases (2017-2033)
8 Heart Failure – Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Heart Failure – Unmet Needs
10 Heart Failure – Key Endpoints of Treatment
11 Heart Failure – Marketed Products
11.1 List of Heart failure Marketed Drugs Across the Top 7 Markets
11.1.1 Atacand (Candesartan cilexetil) – Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Entresto (Sacubitril/valsartan) – Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Verquvo (Vericiguat) – Bayer HealthCare Pharmaceuticals/Merck & Co
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Diovan (Valsartan) – Novartis
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Farxiga (Dapagliflozin) – AstraZeneca
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 Heart Failure – Pipeline Drugs
12.1 List of Heart failure Pipeline Drugs Across the Top 7 Markets
12.1.1 Empagliflozin- Boehringer Ingelheim/Eli Lilly and Company
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Mitiperstat – AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Canagliflozin – Johnson & Johnson/Mitsubishi Tanabe Pharma Corporation
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Omecamtiv mecarbil – Cytokinetics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Rexlemestrocel L – Mesoblast/Teva Pharmaceutical Industries
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Heart Failure – Attribute Analysis of Key Marketed and Pipeline Drugs
14. Heart Failure – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Heart Failure – Market Scenario
15.1 Market Scenario – Key Insights
15.2 Market Scenario – Top 7 Markets
15.2.1 Heart Failure – Market Size
15.2.1.1 Market Size (2017-2022)
15.2.1.2 Market Forecast (2023-2033)
15.2.2 Heart Failure – Market Size by Therapies
15.2.2.1 Market Size by Therapies (2017-2022)
15.2.2.2 Market Forecast by Therapies (2023-2033)
15.3 Market Scenario – United States
15.3.1 Heart Failure – Market Size
15.3.1.1 Market Size (2017-2022)
15.3.1.2 Market Forecast (2023-2033)
15.3.2 Heart Failure – Market Size by Therapies
15.3.2.1 Market Size by Therapies (2017-2022)
15.3.2.2 Market Forecast by Therapies (2023-2033)
15.3.3 Heart Failure – Access and Reimbursement Overview
15.4 Market Scenario – Germany
15.4.1 Heart Failure – Market Size
15.4.1.1 Market Size (2017-2022)
15.4.1.2 Market Forecast (2023-2033)
15.4.2 Heart Failure – Market Size by Therapies
15.4.2.1 Market Size by Therapies (2017-2022)
15.4.2.2 Market Forecast by Therapies (2023-2033)
15.4.3 Heart Failure – Access and Reimbursement Overview
15.5 Market Scenario – France
15.5.1 Heart Failure – Market Size
15.5.1.1 Market Size (2017-2022)
15.5.1.2 Market Forecast (2023-2033)
15.5.2 Heart Failure – Market Size by Therapies
15.5.2.1 Market Size by Therapies (2017-2022)
15.5.2.2 Market Forecast by Therapies (2023-2033)
15.5.3 Heart Failure – Access and Reimbursement Overview
15.6 Market Scenario – United Kingdom
15.6.1 Heart Failure – Market Size
15.6.1.1 Market Size (2017-2022)
15.6.1.2 Market Forecast (2023-2033)
15.6.2 Heart Failure – Market Size by Therapies
15.6.2.1 Market Size by Therapies (2017-2022)
15.6.2.2 Market Forecast by Therapies (2023-2033)
15.6.3 Heart Failure – Access and Reimbursement Overview
15.7 Market Scenario – Italy
15.7.1 Heart Failure – Market Size
15.7.1.1 Market Size (2017-2022)
15.7.1.2 Market Forecast (2023-2033)
15.7.2 Heart Failure – Market Size by Therapies
15.7.2.1 Market Size by Therapies (2017-2022)
15.7.2.2 Market Forecast by Therapies (2023-2033)
15.7.3 Heart Failure – Access and Reimbursement Overview
15.8 Market Scenario – Spain
15.8.1 Heart Failure – Market Size
15.8.1.1 Market Size (2017-2022)
15.8.1.2 Market Forecast (2023-2033)
15.8.2 Heart Failure – Market Size by Therapies
15.8.2.1 Market Size by Therapies (2017-2022)
15.8.2.2 Market Forecast by Therapies (2023-2033)
15.8.3 Heart Failure – Access and Reimbursement Overview
15.9 Market Scenario – Japan
15.9.1 Heart Failure – Market Size
15.9.1.1 Market Size (2017-2022)
15.9.1.2 Market Forecast (2023-2033)
15.9.2 Heart Failure – Market Size by Therapies
15.9.2.1 Market Size by Therapies (2017-2022)
15.9.2.2 Market Forecast by Therapies (2023-2033)
15.9.3 Heart Failure – Access and Reimbursement Overview
16 Heart Failure – Recent Events and Inputs From Key Opinion Leaders
17 Heart Failure Market – SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Heart Failure Market – Strategic Recommendations
19 Appendix